SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-031524
Filing Date
2024-08-13
Accepted
2024-08-13 13:21:51
Documents
61
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 961295
2 ex31-1.htm EX-31.1 18444
3 ex31-2.htm EX-31.2 17786
4 ex32.htm EX-32 8354
  Complete submission text file 0001493152-24-031524.txt   4240015

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pvct-20240630.xsd EX-101.SCH 35537
6 XBRL CALCULATION FILE pvct-20240630_cal.xml EX-101.CAL 44772
7 XBRL DEFINITION FILE pvct-20240630_def.xml EX-101.DEF 129991
8 XBRL LABEL FILE pvct-20240630_lab.xml EX-101.LAB 270824
9 XBRL PRESENTATION FILE pvct-20240630_pre.xml EX-101.PRE 214265
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 539299
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 241200255
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)